References
1. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; Feb 7. doi: 10.1001/jama.2020.1585.
2. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect. 2020; Apr 10. pii: S0163-4453(20)30165-1. doi: 10.1016/j.jinf.2020.03.037.
3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet Jan 2020; 395: 497–506. Doi: 10.1016/S0140-6736(20)30183-5
4. Giamarellos-Bourboulis et al., Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure, Cell Host & Microbe (2020). doi: 10.1016/j.chom.2020.04.009.
5. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet. 2020 Apr 29.
doi.org/10.1016/S0140-6736(20)31022-9
6. Feldman M, Maini RN, Woody JN, Holgate GW, Rowland M et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet published online on 9 April 2020. Doi: 10.1016/S0140-6736(20)30858-8
7. Dettelbach HR, Aviado DM. Clinical pharmacology of pentoxifylline with special reference to its hemorrheologic effect for the treatment of intermittent claudication. J Clin Pharmacol. 1985; 25 :8-26. doi: 10.1002/j.1552-4604.1985.tb02796.x
8. Donate-Correa J, Tagua VG, Ferri C, Martín-Núñez E, Hernández-Carballo C, Ureña-Torres P et al. Pentoxifylline for Renal Protection in Diabetic Kidney Disease. A Model of Old Drugs for New Horizons. J Clin Med. 2019; 8: E287. doi: 10.3390/jcm8030287.
9. Konrad FM, Neudeck G, Vollmer I, Ngamsri KC, Thiel M, Reutershan J. Protective effects of pentoxifylline in pulmonary inflammation are adenosine receptor A2A dependent. FASEB J. 2013; 27:3524-35. doi.org/10.1096/fj.13-228122.
10. Tong Z1, Dai H, Chen B, Abdoh Z, Guzman J, Costabel U. Inhibition of cytokine release from alveolar macrophages in pulmonary sarcoidosis by pentoxifylline: comparison with dexamethasone. Chest. 2003; 124:1526-32. doi: 10.1378/chest.124.4.1526
11. Sunil VR, Vayas KN, Cervelli JA, Malaviya R, Hall L, Massa CB et al. Pentoxifylline attenuates nitrogen mustard-induced acute lung injury, oxidative stress and inflammation. Exp Mol Pathol. 2014; 97: 89-98. Doi: 10.1016/j.yexmp.2014.05.009
12. Chen YM, Ng YY, Lin SL, Chiang WC, Lan HY, Tsai TJ. Pentoxifylline suppresses renal tumour necrosis factor-alpha and ameliorates experimental crescentic glomerulonephritis in rats. Nephrol Dial Transplant. 2004; 19: 1106-15.  Doi: 10.1093/ndt/gfh127
13. Ozturk B, Egehan I, Atavci S, Kitapci M. Pentoxifylline in prevention of radiation- induced lung toxicity in patients with breast and lung cancer: a double-blind randomized trial. Int J Radiat Oncol Biol Phys. 2004; 58: 213-9. Doi: 10.1016/s0360-3016(03)01444-5
14. Ustünsoy H, Sivrikoz MC, Bakir K, Senkaya, Erbagci B, Uçak R et al. The inhibition of pro-inflammatory cytokines with pentoxifylline in the cardiopulmunary bypass lung. Respir Med. 2002; 96: 275-9 https://d-nb.info/109817061X/34
15. Thursz M, Richardson P, Allison M et al. Prednisolone or Pentoxifylline for alcoholic hepatitis. N Eng J Med 2015;372:1619-1628. doi:10.1056/NEJMoa1412278.
16. Marques LJ, Zheng L, Poulakis N, Guzman J, Costabel U. Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. Am J Respir Crit Care Med. 1999;159(2):508-11. doi:10.1164/ajrccm.159.2.9804085.
17. Rainsford KD. Influenza (“Bird Flu”), inflammation and anti-inflammatory/analgesic drugs. Inflammopharmacology. 2006; 14: 2-9. doi: 10.1007/s10787-006-0002-5
18. Parameswaram N and Patial S. Tumor Necrosis Factor-α Signaling in Macrophages. Crit Rev Eukaryot Gene Expr. 2010 March 30;20(2):87–103. Parameswaran N, Patial S. Tumor necrosis factor-α signaling in macrophages. Crit Rev Eukaryot Gene Expr. 2010;20(2):87–103. doi:10.1615/critreveukargeneexpr.v20.i2.10
19. Brauer R, Chen P. Influenza leaves a Trail to pulmonary Oedema. J Clin Invest. 2016;126(4):1245–1247. doi:10.1172/JCI86802
20. Ackermann M, Verleden SE, Kuehnel M et al. Pulmonary Vascular Endothelialitis, Thrombosis, and angiogenesis in COVID-19. NEJM May 21 2020. Doi: 10.1056/NEJMoa2015432